Akero re­turns with more MASH da­ta to back PhI­II drug, touts fi­bro­sis re­sponse rate

Akero Ther­a­peu­tics is back with more da­ta for its FGF21 ana­log in meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH), a dis­ease space that’s been plagued by a string of fail­ures but has re­cent­ly seen a re­ju­ve­na­tion of in­ter­est due to GLP-1 da­ta and the po­ten­tial ap­proval of a treat­ment as ear­ly as this month.

The drug can­di­date, efrux­ifer­min, is al­ready in a Phase III pro­gram re­cruit­ing a va­ri­ety of MASH pa­tients. In re­sponse to Mon­day’s da­ta, Akero’s stock $AKRO jumped by as much as 72% to $48 pre­mar­ket, and then set­tled at around $32.86 (an 18% jump) once the mar­ket opened.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER